Indication
Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Loading your page…
Loading your page…
Psoriasis
Marketing Authorisation Holder: Almirall, S.A.
EMA Authorisation: 17/09/2018
INN: tildrakizumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ilumetri: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.